Lin Ye

6PUBLICATIONS
8CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Medical microbiology not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 22, 2026
Association between emotional distress and efficacy of immune checkpoint inhibitors in patients with hepatocellular carcinoma: a multicentre, prospective observational study protocol.

|Jul 22, 2026
Stage-Dependent Efficacy of TACE Combined with Tyrosine Kinase and Immune Checkpoint Inhibitors as Conversion Therapy for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study.

|Jun 07, 2026
Efficacy of targeted hepatocellular carcinoma therapy using modified response evaluation criteria in solid tumors and alpha-fetoprotein: A single center retrospective exploratory study.

|Mar 09, 2026
Successful Immune Checkpoint Inhibitor Rechallenge After Sintilimab-Induced Pancreatitis: A Case Report.

Hao Shi, Lin Ye, Qinrong Mo

|Oct 22, 2025
Acute rupture of primary hepatic angiosarcoma with Kasabach-Merritt syndrome: a rare case report and literature review.

Lin Ye, Wanrong Yue, Hao Shi

|Feb 05, 2025
Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages.

Da-Long Yang, Lin Ye, Fan-Jian Zeng

Pageof 1

Frequent Collaborators

3 joint publications

Yaqun Yu

1 joint publications

Da-Long Yang

1 joint publications

Liang Ma

1 joint publications

Jian-Hong Zhong